We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 170 results
  1. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

    This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and...

    Kensuke Usuki, Shigeki Ohtake, ... Yasushi Miyazaki in International Journal of Hematology
    Article 28 November 2023
  2. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

    We conducted a multicenter, prospective observational study of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic...

    Kensuke Usuki, Shigeki Ohtake, ... Hitoshi Kiyoi in International Journal of Hematology
    Article 13 December 2023
  3. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT

    Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndrome (MDS). However, whether...

    Noriharu Nakagawa, Ken Ishiyama, ... Yasushi Miyazaki in Annals of Hematology
    Article 08 November 2023
  4. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group

    This phase 1/2 study aimed to identify the maximum tolerated dose, the recommended phase 2 dose (RP2D), and efficacy of the clofarabine, etoposide,...

    Takeshi Saito, Yoshihiro Hatta, ... Yasushi Miyazaki in International Journal of Hematology
    Article 23 November 2020
  5. Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group

    We conducted a nationwide questionnaire-based survey in 2019 following 2001, 2007 and 2013 surveys to clarify the real-world management of infection...

    Shun-ichi Kimura, Hiroyuki Fujita, ... Yasushi Miyazaki in International Journal of Hematology
    Article 18 June 2020
  6. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy

    The optimal treatment for Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) has not been...

    Shinichi Kako, Fumihiko Hayakawa, ... Yoshiko Atsuta in International Journal of Hematology
    Article 30 July 2021
  7. Guest editorial: recent progress in pediatric leukemia

    Recent progress in comprehensive genomic analysis and well-designed clinical trials has dramatically improved the treatment strategies for pediatric...

    Article 13 January 2023
  8. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial

    The hypomethylating agent azacitidine (AZA) significantly extends overall survival (OS) in patients with higher risk myelodysplastic syndromes (MDS),...

    Yasushi Miyazaki, Toru Kiguchi, ... Sumihisa Honda in International Journal of Hematology
    Article 04 May 2022
  9. Recent progress in pediatric lymphoblastic leukemia

    The probability of long-term survival for children with lymphoblastic leukemia has improved dramatically over recent decades, mainly owing to...

    Article 01 December 2022
  10. Promoter swap** of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia

    Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a subset of ALL that demonstrated a high treatment failure rate. One of the...

    Bunpei Miyazaki, Toshihide Ueno, ... Yosuke Tanaka in npj Precision Oncology
    Article Open access 09 December 2023
  11. Treatment for relapsed acute promyelocytic leukemia

    The advent of all- trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved the outcomes of acute promyelocytic leukemia...

    Masamitsu Yanada in Annals of Hematology
    Article 16 August 2022
  12. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era

    Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the...

    Yumiko Toda, Masahiro Ashizawa, ... Yoshinobu Kanda in International Journal of Hematology
    Article 05 April 2024
  13. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia

    We compared the outcomes of autologous stem cell transplantation (auto-SCT) with those of allogeneic stem cell transplantation (allo-SCT) from a...

    Shuichi Mizuta, Tomotaka Ugai, ... Shinichi Kako in International Journal of Hematology
    Article 10 May 2022
  14. Cancer in adolescents and young adults in Japan: epidemiology and cancer strategy

    According to national cancer registry data in Japan, approximately 20,000 adolescents and young adults (AYAs, age 15–39 years) are newly diagnosed...

    Kayo Nakata, Eiso Hiyama, ... Isao Miyashiro in International Journal of Clinical Oncology
    Article Open access 15 November 2021
  15. A novel RARASNX15 fusion in PMLRARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1)

    Acute promyelocytic leukemia (APL) is characterized by a series of retinoic acid receptor (RAR) fusion genes that lead to the dysregulation of RAR...

    Kentaro Hirade, Shigeru Kusumoto, ... Yukiya Yamamoto in International Journal of Hematology
    Article 19 July 2022
  16. Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission

    Acute lymphoblastic leukemia (ALL) in adults is associated with poor outcomes as compared to children when treated with chemotherapy, leading to a...

    Shukaib Arslan, Vinod Pullarkat, Ibrahim Aldoss in Current Treatment Options in Oncology
    Article 07 June 2021
  17. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia

    Significant advancements have been achieved with regard to the outcomes of acute promyelocytic leukemia (APL) patients through the introduction of...

    Hitoshi Minamiguchi, Hiroyuki Fujita, ... Akihiro Takeshita in Annals of Hematology
    Article 02 September 2020
  18. Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant

    Purpose of Review

    Over the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia...

    Kunhwa Kim, Elias Jabbour, ... Farhad Ravandi in Current Oncology Reports
    Article 14 June 2021
Did you find what you were looking for? Share feedback.